MedTrace Logo

The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms

NCT04854759 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2021-08-13

No results posted yet for this study

Summary

The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus. Multicenter randomized, double-blind, placebo-controlled, non-commercial clinical trial

Conditions

Interventions

DRUG

Amantadine Hydrochloride

100 mg, capsule

DRUG

Placebo

100 mg, capsule

Sponsors & Collaborators

  • Independent Public Clinical Hospital No. 4 in Lublin

    lead OTHER

Principal Investigators

  • Konrad Rejdak, Professor, PhD, MD · Independent Public Clinical Hospital No. 4 in Lublin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-15
Primary Completion
2022-03-31
Completion
2022-05-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04854759 on ClinicalTrials.gov